Rodrigue Tinfang, MD
Family Medicine · Chicago, ILNPI 1033290481
Payments from drug & device makers
Across 64 payments — averaging $23.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$296
- AbbVie$246
- Lilly USA, LLC$196
- E.r. Squibb & Sons, L.L.C.$120
- Vivus LLC$85
- Novartis$78
- plus $488 from 13 others
What the payments were for
- Food & beverage$1,510100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 4 | $296 |
| AbbVie(2 entities) | 13 | $246 |
| Lilly USA, LLC | 5 | $196 |
| E.r. Squibb & Sons, L.L.C. | 8 | $120 |
| Vivus LLC | 5 | $85 |
| Novartis | 4 | $78 |
| Preventric Diagnostics, Inc. | 2 | $73 |
| Boehringer Ingelheim | 3 | $72 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $66 |
| Pfizer | 3 | $54 |
| Xeris Pharmaceuticals, Inc. | 3 | $52 |
| GSK | 3 | $44 |
| Novo Nordisk | 1 | $21 |
| Ardelyx, Inc. | 1 | $21 |
| Merck | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Cranial Technologies, Inc | 1 | $17 |
| Gilead | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$222
How this compares
$1,510 in reported general payments places this provider in the 75th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 148 | $105,197 |
| OzempicSemaglutide | 54 | $51,824 |
| EliquisApixaban | 80 | $51,017 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $49,360 |
| TradjentaLinagliptin | 55 | $49,255 |
| LinzessLinaclotide | 80 | $49,179 |
| XareltoRivaroxaban | 32 | $24,035 |
| JanuviaSitagliptin Phosphate | 16 | $18,501 |
| MyrbetriqMirabegron | 25 | $15,070 |
| FarxigaDapagliflozin Propanediol | 15 | $13,116 |
| Incruse ElliptaUmeclidinium Bromide | 32 | $12,186 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $9,619 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 30 | $8,924 |
| RestasisCyclosporine | 13 | $8,635 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $8,242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $72 | $154,452203 claims |
| AbbVieLinzess, Restasis | $246 | $57,81493 claims |
| Novo NordiskOzempic | $21 | $51,82454 claims |
| PfizerEliquis | $54 | $51,01780 claims |
| GileadBiktarvy | $16 | $49,36012 claims |
| GSKIncruse Ellipta, Arnuity Ellipta, Breo Ellipta | $44 | $26,04783 claims |
| Johnson & JohnsonXarelto | $296 | $24,03532 claims |
| MerckJanuvia | $19 | $18,50116 claims |
| AstraZenecaFarxiga | $18 | $13,11615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Chicago
- Bradley TorphyChicago$3M
- Frank PhillipsChicago$1.6M
- Ayoade AkereChicago$484K
- Sandy GibsonChicago$309K
- Mandy GittlerChicago$204K
- Jacqueline OlivoChicago$165K
- Sameer PanjwaniChicago$136K
- Igor AltmanChicago$64K
- Juan RojasChicago$40K
- Mark SimonChicago$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.